Ghrelin Alleviates Mdma-Induced Disturbance of Serum Glucose and Lipids Levels in the Rat

Hepatotoxicity is one of the clinically adverse effects of ecstasy (3, 4-methylenedioxymethamphetamine; mdma) consumption. the detoxification tissue, liver, plays a central role in maintaining circulating levels of glucose and lipid. hypoglycemia and hypotriglyceridemia have been reported due to ecstasy abuse. ghrelin is a 28-amino-acid peptide secreted predominantly from the stomach. it has been demonstrated that ghrelin has hepatoprotective effects and is able to increase blood glucose concentration. in the current study, we explored the effect of hepatotoxic dose of mdma and therapeutic use of exogenous ghrelin on the serum levels of glucose and lipids in four groups of rats. mdma caused a severe and transient reduction in circulating levels of glucose and triglyceride and increased serum ldl. however, cholesterol and hdl levels remained unchanged. meanwhile, altered hepatic architecture was observed with intracellular vacuolation that may indicate intracellular accumulation of lipid droplets. in addition, following ghrelin administration, the blood sugar levels improved and ldl levels returned to the baseline value, and ghrelin treatment did not improve triglycerides levels. these results showed that mdma causes hypoglycemia, hypotriglyceridemia, and hyper ldl-cholesterolemia. to our knowledge, this is the first report showing ghrelin administration could improve hypoglycemia and normalize ldl levels induced by mdma and partially restore hepatic architecture.